Program
CDX-622
A development code.
Its studies are mostly in Asthma, led by Celldex Therapeutics.
Furthest: phase 1, since Oct 18, 20242 company-led studies, 1 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Celldex Therapeutics | 21 open or running | phase 1since Oct 18, 2024 | Oct 18, 2024 | Mar 2027phase 1 · NCT07330778 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 18, 2024First study: phase 1 study in Healthy ParticipantsFirst studyNCT06650761 · 85 enrolled · United States
- Sep 26, 2025Phase 1 study in AsthmaNCT07330778 · 12 planned · United States
Ahead
- Mar 2027Primary completion: phase 1 study in AsthmaNCT07330778
TargetBeta
“CDX-622 is a bispecific antibody that binds to stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP).”study text, by rule · the study
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07330778Asthma · United States | 1 | Recruiting | Mar 2027 | 12 |
| NCT06650761Healthy Participants · United States | 1 | Completed | Apr 24, 2026 | 85 |
How it is read
Names in the registry
- “CDX-622”, 2 entries
Codes read as this program: CDX622.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.